- Exchange: EN Brussels
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for UCB SA (UCB)
| Open: | 44.7500 | Day's Range: | 43.9850 - 44.8100 | Volume: | 176,900 |
|---|---|---|---|---|---|
| Previous Close: | 44.5550 | 52wk Range: | 36.3550 - 50.2400 | 1-Yr Rtn: | +18.56% |
Key Statistics for UCB
| Current P/E Ratio (ttm) | 33.1791 |
|---|---|
| Estimated P/E(12/2013) | 22.7763 |
| Relative P/E vs. BEL20 | 1.1479 |
| Earnings Per Share (EUR) (ttm) | 1.3352 |
| Est. EPS (EUR) (12/2013) | 1.9450 |
| Est. PEG Ratio | 1.7413 |
| Market Cap (M EUR) | 8,125.39 |
| Shares Outstanding (M) | 183.42 |
| 30 Day Average Volume | 263,791 |
| Price/Book (mrq) | 1.7089 |
| Price/Sale (ttm) | 2.5832 |
| Dividend Indicated Gross Yield | 2.30% |
| Cash Dividend (EUR) | 0.7650 |
| Last Dividend | 05/02/2013 |
| 5 Year Dividend Growth | 2.09% |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for UCB
Company Profile & Key Executives for UCB
UCB SA is a biopharmaceutical company. The Company specializes in the treatment of central nervous system disorders, inflammatory diseases, and oncology. UCB operates worldwide.
| Roch F DoliveuxChief Executive Officer | Detlef ThielgenExec VP/CFO |
| Ismail KolaExec VP/Pres:Newmedicines | Anna S RichoExec VP/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
UCB News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page